pSivida eyes Iluvian
Friday, 13 March, 2009
pSivida has reported good interim results in its Phase II study of the intra-vitreal insert Iluvien.
The 36-month open label study is being conducted by pSivida’s licensing partner Alimera Sciences and is being run concurrently with a Phase III trial of a corticosteroid in patients with diabetic macular oedema.
Data from the first 12 months showed no adverse events in lose dose patients while there was a small increase in intra-ocular pressure in high dose patients.
Iluvian delivers the drug fluocinolone acetonide directly into the eye. pSivida has licensed two other ophthalmic products, Retisert and Vitrasert, to Bausch & Lomb.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
